Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Employer Drug Coverage Will Shift To Part D, Stakeholders Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies will accept the government subsidy for retirees’ drug coverage initially, but will move former workers to the Medicare drug benefit in later years, executives from Kaiser Foundation Health Plans and the Employers Coalition on Medicare predict.

You may also be interested in...



Most Employers’ Retiree Rx Coverage Will Continue After Medicare Part D – Survey

Kaiser Family Foundation/Hewitt survey finds 58% of large employers plan to accept the government subsidy to continue offering retiree drug benefits that are actuarially equivalent to Part D. Only 8% expect to discontinue retiree Rx coverage.

Most Employers’ Retiree Rx Coverage Will Continue After Medicare Part D – Survey

Kaiser Family Foundation/Hewitt survey finds 58% of large employers plan to accept the government subsidy to continue offering retiree drug benefits that are actuarially equivalent to Part D. Only 8% expect to discontinue retiree Rx coverage.

Broad Medicare Formularies Would Negatively Impact Rx Industry, PCMA Says

Limiting PBMs’ ability to control costs in Medicare Rx would benefit advocates of a government-run health care system, Pharmaceutical Care Management Association CEO Merritt says. Broad drug formularies also would increase costs for employers, he says.

Topics

UsernamePublicRestriction

Register

PS057869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel